4.77
0.17 (3.70%)
| Previous Close | 4.60 |
| Open | 4.70 |
| Volume | 1,927,803 |
| Avg. Volume (3M) | 1,195,808 |
| Market Cap | 256,754,784 |
| Price / Sales | 1.79 |
| Price / Book | 0.570 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Profit Margin | -79.94% |
| Operating Margin (TTM) | -2,318.99% |
| Diluted EPS (TTM) | -2.05 |
| Quarterly Revenue Growth (YOY) | 5,556.00% |
| Total Debt/Equity (MRQ) | 2.33% |
| Current Ratio (MRQ) | 9.00 |
| Operating Cash Flow (TTM) | -130.36 M |
| Levered Free Cash Flow (TTM) | -35.38 M |
| Return on Assets (TTM) | -15.49% |
| Return on Equity (TTM) | -23.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Prothena Corporation plc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.75 |
|
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 19.01% |
| % Held by Institutions | 88.20% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 81.00 (Piper Sandler, 1,598.11%) | Buy |
| Median | 18.00 (277.36%) | |
| Low | 4.00 (B of A Securities, -16.14%) | Sell |
| Average | 29.20 (512.16%) | |
| Total | 4 Buy, 1 Sell | |
| Avg. Price @ Call | 4.58 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 28 May 2025 | 4.00 (-16.14%) | Sell | 4.60 |
| Chardan Capital | 27 May 2025 | 18.00 (277.36%) | Buy | 4.58 |
| 09 May 2025 | 40.00 (738.57%) | Buy | 7.43 | |
| HC Wainwright & Co. | 27 May 2025 | 14.00 (193.50%) | Buy | 4.58 |
| 09 May 2025 | 30.00 (528.93%) | Buy | 7.43 | |
| JMP Securities | 27 May 2025 | 29.00 (507.97%) | Buy | 4.58 |
| 09 May 2025 | 78.00 (1,535.22%) | Buy | 7.43 | |
| Piper Sandler | 27 May 2025 | 81.00 (1,598.11%) | Buy | 4.58 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 May 2025 | Announcement | Prothena Reports First Quarter 2025 Financial Results and Business Highlights |
| 01 May 2025 | Announcement | Prothena to Report First Quarter 2025 Financial Results on May 8 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |